1.Construction and application effects of CAI secondary prevention model in nursing staff
Fengjuan LU ; Caixia WU ; Shibing GUAN ; Lianjie CHENG ; Ya′nan ZHANG ; Zhengxiang LI
Chinese Journal of Modern Nursing 2016;22(20):2830-2835
Objective To study the clinical effect of the secondary prevention of chronic ankle instability (CAI) for nursing staff.Methods From September 2014 to January 2015, we screened 100 nurse with functional ankle instability in Shandong Provincial Hospital .The subjects were divided into the intervention group ( n=51 ) and the control group ( n =49 ) by random number table .The nurses of intervention group accepted measures of the secondary prevention , including bundle health education , bracing and rehabilitation , while the nurses of control group received only routine health education .Before intervention and 4 months later , we evaluated the ankle instability by Chinese version Cumberland ankle instability tool ( CAIT) in two groups and compared the intervention effects and relevant knowledge of the two groups .Results Before the intervention, the CAIT score of intervention group was (19.0 ±4.8), and was (28.2 ±3.0) after intervention ( t=9.210,P<0.05);the CAIT score in the control group was (19.0 ±5.1) before intervention and (21.3 ± 5.2) after intervention (t=1.509,P>0.05); after intervention, the difference of two groups had statistical significance (t=9.317,P<0.05).Conclusions The secondary prevention of CAI can improve CAI nurse staff′s ankle stability and the recognition level of CAI prevention knowledge , and promote the clinical symptom prevention effectively , so it has significance for the improvement of nurse′s ankle function .
2.Predictive factors of pathological complete response after neoadjuvant chemoradiotherapy for middle-low rectal cancer
Qizhi LIU ; Hang ZHANG ; Liqiang HAO ; Zheng LOU ; Lianjie LIU ; Xianhua GAO ; Haifeng GONG ; Yonggang HONG ; Cheng XIN ; Wei ZHANG
Chinese Journal of Gastrointestinal Surgery 2020;23(12):1159-1163
Objective:To explore the predictive factors of pathological complete response (pCR) after neoadjuvant chemoradiotherapy for middle-low rectal cancer.Methods:A case-control study was conducted. The inclusion criteria were as follows: (1) colonoscopy, digital examination or magnetic resonance imaging (MRI) showed a distance from the lower edge of the tumor to the dentate line of no more than 10 cm; (2) complete clinicopathological data were available; (3) preoperative biopsy revealed adenocarcinoma; (4) preoperative pelvic MRI or endorectal ultrasonography was performed; (5) no distant metastasis was found. Exclusion criteria: (1) preoperative radiotherapy and chemotherapy were not administrated according to the standard; (2) simultaneous multiple primary cancer and familial adenomatous polyposis were observed. According to the above criteria, clinicopathological data of 245 patients with middle-low rectal cancer undergoing preoperative neoadjuvant chemoradiotherapy in Changhai Hospital of Navy Medical University from January 2012 to December 2019 were retrospectively collected. Univariate analysis and multivariate logistic analysis were used to identify the clinical factors predicting pCR. pCR is defined as complete disappearance of cancer cells under the microscope in cancer specimens (including lymph nodes) after neoadjuvant chemoradiotherapy.Results:A total of 72 patients with pCR were enrolled in this study. Univariate analysis showed that preoperative T stage, tumor circumference, tumor morphology, carbohydrate antigen (CA) 19-9, interval between the end of neoadjuvant therapy and operation were associated with pCR (all P<0.05). The above 5 variables were included in multivariate logistic analysis and the results revealed that the T stage (OR=5.743, 95% CI: 2.416-13.648, P<0.001), tumor circumference (OR=7.754, 95% CI: 3.822-15.733, P<0.001), tumor morphology (OR=0.264, 95% CI: 0.089-0.786, P=0.017) and the interval between the end of neoadjuvant therapy and operation (OR=0.303, 95% CI: 0.147-0.625, P=0.001) were independent predictive factors of pCR, while CA 19-9 level was not an independent factor (OR=1.873, 95% CI:0.372-9.436, P=0.447). Conclusion:By knowing the clinical features of preoperative T stage, tumor circumference, tumor morphology and the interval between neoadjuvant chemoradiotherapy and operation, patients with higher likelyhood of pCR after neoadjuvant chemoradiotherapy may be identified.
3.Predictive factors of pathological complete response after neoadjuvant chemoradiotherapy for middle-low rectal cancer
Qizhi LIU ; Hang ZHANG ; Liqiang HAO ; Zheng LOU ; Lianjie LIU ; Xianhua GAO ; Haifeng GONG ; Yonggang HONG ; Cheng XIN ; Wei ZHANG
Chinese Journal of Gastrointestinal Surgery 2020;23(12):1159-1163
Objective:To explore the predictive factors of pathological complete response (pCR) after neoadjuvant chemoradiotherapy for middle-low rectal cancer.Methods:A case-control study was conducted. The inclusion criteria were as follows: (1) colonoscopy, digital examination or magnetic resonance imaging (MRI) showed a distance from the lower edge of the tumor to the dentate line of no more than 10 cm; (2) complete clinicopathological data were available; (3) preoperative biopsy revealed adenocarcinoma; (4) preoperative pelvic MRI or endorectal ultrasonography was performed; (5) no distant metastasis was found. Exclusion criteria: (1) preoperative radiotherapy and chemotherapy were not administrated according to the standard; (2) simultaneous multiple primary cancer and familial adenomatous polyposis were observed. According to the above criteria, clinicopathological data of 245 patients with middle-low rectal cancer undergoing preoperative neoadjuvant chemoradiotherapy in Changhai Hospital of Navy Medical University from January 2012 to December 2019 were retrospectively collected. Univariate analysis and multivariate logistic analysis were used to identify the clinical factors predicting pCR. pCR is defined as complete disappearance of cancer cells under the microscope in cancer specimens (including lymph nodes) after neoadjuvant chemoradiotherapy.Results:A total of 72 patients with pCR were enrolled in this study. Univariate analysis showed that preoperative T stage, tumor circumference, tumor morphology, carbohydrate antigen (CA) 19-9, interval between the end of neoadjuvant therapy and operation were associated with pCR (all P<0.05). The above 5 variables were included in multivariate logistic analysis and the results revealed that the T stage (OR=5.743, 95% CI: 2.416-13.648, P<0.001), tumor circumference (OR=7.754, 95% CI: 3.822-15.733, P<0.001), tumor morphology (OR=0.264, 95% CI: 0.089-0.786, P=0.017) and the interval between the end of neoadjuvant therapy and operation (OR=0.303, 95% CI: 0.147-0.625, P=0.001) were independent predictive factors of pCR, while CA 19-9 level was not an independent factor (OR=1.873, 95% CI:0.372-9.436, P=0.447). Conclusion:By knowing the clinical features of preoperative T stage, tumor circumference, tumor morphology and the interval between neoadjuvant chemoradiotherapy and operation, patients with higher likelyhood of pCR after neoadjuvant chemoradiotherapy may be identified.
4. Effects of artesunate combined with bortezomib on apoptosis and autophagy of acute myeloid leukemia cells in vitro and its mechanism
Lianjie HU ; Tao JIANG ; Fujue WANG ; Shihua HUANG ; Xiaomin CHENG ; Yongqian JIA
Chinese Journal of Hematology 2019;40(3):204-208
Objective:
To investigate the effects of artesunate combined with bortezomib on the proliferation, apoptosis and autophagy of human acute myeloid leukemia cell lines MV4-11, and its mechanisms.
Methods:
MTT method was used to determine the anti-proliferation effect of different concentrations of artesunate, bortezomib and their combination on MV4-11 cells. The cell apoptosis were analyzed by flow cytometry. The expression of cleaved-Caspase-3, Bcl-2 family protein (Bcl-2, Mcl-1, Bim, Bax) and autophagy-related protein LC3B were assayed by Western blot.
Results:
Artesunate displayed a proliferation inhibition effect on MV4-11 with dose- and time-dependent manner, the IC50 of artesunate on MV4-11 after 48 hours was 1.44 μg/ml. Bortezomib displayed a proliferation inhibition effect on MV4-11 with dose-dependent manner, the IC50 of bortezomib on MV4-11 after 48 hours was 8.97 nmol/L. The combination of artesunate (0.75, 1.0 μg/ml) and Bortezomib (6, 8 nmol/L) showed higher inhibition on MV4-11 than artesunate or bortezomib alone in the same concentration gradient after 48 hours (